ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson’s disease

Antonini, Angelo; Barone, Paolo; Bonuccelli, Ubaldo; Annoni, K.; Asgharnejad, Mahnaz; Stanzione, Paolo

doi:10.1136/jnnp-2016-315277

Cited by 127 publications

(175 citation statements)

References 38 publications

Supporting

Mentioning

150

Contrasting

Unclassified

Order By: Relevance

“…The disadvantage of QUIP is its low specificity but high sensitivity. In a direct comparison of QUIP and MIDI, the prevalence of ICB by QUIP has been 5% higher than MIDI (Antonini et al., 2017). Moreover, QUIP was positive in 20.3% in healthy subjects (Weintraub, Papay, & Siderowf, 2013).…”

Section: Discussionmentioning

confidence: 99%

“…Overall, patients in the ICB persister group were younger, pergolide use than ICB remitters. Younger age and pergolide use have been reported to be risk factors for the development of ICB (Antonini et al., 2017; Weintraub et al., 2006, 2015; Zurowski & O'Brien, 2015). Our findings suggest that these factors may also be related to the persistence of ICB.…”

Section: Discussionmentioning

confidence: 99%

“…Being male has been reported as a risk factor for the development of ICB (Antonini et al., 2017; Weintraub, Koester, et al., 2010; Weintraub, et al., 2015; Zurowski & O'Brien, 2015). Both L‐DOPA induced dyskinesia (LID), and ICB can be induced by excessive dopaminergic stimulation in the motor or limbic territories of the striatum (Jimenez‐Urbieta et al., 2015; Rocha, Gago, Barbosa, Cavaleiro, & Laranjinha, 2015).…”

Section: Discussionmentioning

confidence: 99%

“…Impulse control behaviors (ICBs) consist of ICDs and a number of closely related behaviors, including punding, hobbyism, walkabout, and dopamine dysregulation syndrome (DDS) (Zurowski & O'Brien, 2015). The prevalence of ICD or ICB has been reported to be 3.5%–58.3% in patients with Parkinson's disease (PD) (Antonini et al., 2017; Callesen, Weintraub, Damholdt, & Moller, 2014; Erga, Alves, Larsen, Tysnes, & Pedersen, 2017; Fan, Ding, Ma, & Chan, 2009; Rodriguez‐Violante, Gonzalez‐Latapi, Cervantes‐Arriaga, Camacho‐Ordonez, & Weintraub, 2014; Vela et al., 2016). ICB is an important nonmotor complication in patients with PD because it is associated with functional impairment, decreased quality of life and increased caregiver burden (Weintraub, David, Evans, Grant, & Stacy, 2015).…”

Section: Introductionmentioning

confidence: 99%

“…A number of cross‐sectional studies of ICB in PD have been conducted, but longitudinal assessments have been less reported (Antonini et al., 2017; Avila, Cardona, Martin‐Baranera, Bello, & Sastre, 2011; Bastiaens, Dorfman, Christos, & Nirenberg, 2013; Mamikonyan et al., 2008; Siri et al., 2015; Smith, Xie, & Weintraub, 2016; Sohtaoglu, Demiray, Kenangil, Ozekmekci, & Erginoz, 2010) and little is known about the course or change in ICB according to the type of medication. ICBs are not permanent symptoms and can go into remission (Avila et al., 2011; Mamikonyan et al., 2008; Siri et al., 2015; Sohtaoglu et al., 2010).…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

The factors associated with impulse control behaviors in Parkinson's disease: A 2‐year longitudinal retrospective cohort study

et al. 2018

View full text Add to dashboard Cite

IntroductionImpulse control behaviors (ICBs) are impulsive–compulsive behaviors often associated with dopamine replacement therapy in Parkinson's disease (PD). Although remission can occur in ICB, only four reports on the ratio of remission and the persistence of ICB have been published, and the associated factors with ICB remission or persistence have been little known. Therefore, we conducted a longitudinal assessment of the remission, persistence, and development of ICB and those associated factors in patients with PD.MethodsWe retrospectively investigated a PD database at Aomori Prefectural Central Hospital, Japan. One hundred and forty‐eight patients with PD who could be followed up for 2 years were enrolled. ICB was assessed using the Questionnaire for Impulsive–Compulsive Disorders in Parkinson's disease. Motor severity (Hoehn and Yahr scale and United Parkinson's Disease Rating Scale), cognitive function (Mini–Mental State Examination), and other clinical variables (sex, age, onset age, disease duration, olfactory dysfunction, and dyskinesia) and medications used to treat PD were assessed. Univariate analyses were performed.ResultsSeven patients were excluded because of the exclusion criteria, and 141 patients were analyzed. Thirty patients (21.3%) had ICB at baseline, and these patients also had significantly higher use of pergolide. The ICB remission rate was 60%, the ICB persistence ratio was 40%, and the ICB development ratio was 12.6% over 2 years. Statistically, younger age and pergolide use were associated with ICB persistence. Being male, having dyskinesia, and rotigotine, entacapone, zonisamide, and istradefylline use were associated with ICB development.ConclusionThis study suggests that younger age and pergolide use may be the new associated factors with ICB persistence and that entacapone, zonisamide, and istradefylline use may be associated with the development of ICB. Drug profiles and medication practices in Japan may explain the association of these factors with ICB.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The factors associated with impulse control behaviors in Parkinson's disease: A 2‐year longitudinal retrospective cohort study

et al. 2018

View full text Add to dashboard Cite

show abstract

Prevalence and impact of neuropsychiatric symptoms in normal aging and neurodegenerative syndromes: A population‐based study from Latin America

Rodriguez Salgado,

Acosta,

Kim

et al. 2023

Alzheimer's & Dementia

View full text Add to dashboard Cite

BACKGROUNDNeuropsychiatric symptoms (NPSs) are common in neurodegenerative diseases; however, little is known about the prevalence of NPSs in Hispanic populations.METHODSUsing data from community‐dwelling participants age 65 years and older enrolled in the 10/66 study (N = 11,768), we aimed to estimate the prevalence of NPSs in Hispanic populations with dementia, parkinsonism, and parkinsonism‐dementia (PDD) relative to healthy aging. The Neuropsychiatric Inventory Questionnaire (NPI‐Q) was used to assess NPSs.RESULTSNPSs were highly prevalent in Hispanic populations with neurodegenerative disease; approximately 34.3%, 56.1%, and 61.2% of the participants with parkinsonism, dementia, and PDD exhibited three or more NPSs, respectively. NPSs were the major contributor to caregiver burden.DISCUSSIONClinicians involved in the care of elderly populations should proactively screen for NPSs, especially in patients with parkinsonism, dementia, and PPD, and develop intervention plans to support families and caregivers.HIGHLIGHTS Neuropsychiatric symptoms (NPSs) are highly prevalent in Hispanic populations with neurodegenerative diseases. In healthy Hispanic populations, NPSs are predominantly mild and not clinically significant. The most common NPSs include depression, sleep disorders, irritability, and agitation. NPSs explain a substantial proportion of the variance in global caregiver burden.

show abstract

The Prevalence and Determinants of Neuropsychiatric Symptoms in Late‐Stage Parkinsonism

Hommel

Meinders²,

Lorenzl

et al. 2020

Movement Disord Clin Pract

View full text Add to dashboard Cite

BackgroundBackground: Late-stage parkinsonism and Parkinson's disease (PD) are insufficiently studied population. Although neuropsychiatric symptoms (eg, psychosis, depression, anxiety, behavioral problems) are frequently present, their prevalence and clinical predictors remain unknown. Objective Objective: To determine the prevalence and predictors of neuropsychiatric symptoms in late-stage PD. Methods Methods: We conducted a multinational study of patients with PD with ≥7 years disease duration and either a Hoehn and Yahr stage ≥4 or a Schwab and England score ≤ 50% in the on stage. Neuropsychiatric symptoms were assessed through interviews with carers using the Neuropsychiatric Inventory, with a frequency × severity score ≥ 4, indicating clinically relevant symptoms. The determinants analyzed were demographic characteristics, medication, and motor and nonmotor symptoms. Univariate and multivariate logistic analyses were performed on predictors of clinically relevant neuropsychiatric symptoms. Results Results: A total of 625 patients were recruited in whom the Neuropsychiatric Inventory could be completed. In 92.2% (576/625) of the patients, at least 1 neuropsychiatric symptom was present, and 75.5% (472/625) had ≥1 clinically relevant symptom. The most common clinically relevant symptoms were apathy (n = 242; 38.9%), depression (n = 213; 34.5%), and anxiety (n = 148; 23.8%). The multivariate analysis revealed unique sets of predictors for each symptom, particularly the presence of other neuropsychiatric features, cognitive impairment, daytime sleepiness. Conclusion Conclusion:Neuropsychiatric symptoms are common in late-stage PD. The strongest predictors are the presence of other neuropsychiatric symptoms. Clinicians involved in the care for patients with late-stage PD should be aware of these symptoms in this specific disease group and proactively explore other psychiatric comorbidities once a neuropsychiatric symptom is recognized.

show abstract

ICARUS study: prevalence and clinical features of impulse control disorders in Parkinson’s disease

Abstract: Prevalence of ICD behaviours was relatively stable across the 2-year observational period. ICD-positive patients had more severe depression, poorer sleep quality and reduced quality of life.

Cited by 127 publications

References 38 publications

The factors associated with impulse control behaviors in Parkinson's disease: A 2‐year longitudinal retrospective cohort study

The factors associated with impulse control behaviors in Parkinson's disease: A 2‐year longitudinal retrospective cohort study

Prevalence and impact of neuropsychiatric symptoms in normal aging and neurodegenerative syndromes: A population‐based study from Latin America

The Prevalence and Determinants of Neuropsychiatric Symptoms in Late‐Stage Parkinsonism

Contact Info

Product

Resources

About